Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials
This study was designed to assess the effect of additional spironolactone on blood pressure in patients with resistant hypertension. MEDLINE, EMBASE, and Cochrane Library were searched to identify randomized controlled trials (RCTs) that determined the effect of add-on spironolactone on blood pressu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-04-01
|
| Series: | Clinical and Experimental Hypertension |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/10641963.2016.1246564 |
| _version_ | 1797681550016380928 |
|---|---|
| author | Liping Liu Bing Xu Yunfeng Ju |
| author_facet | Liping Liu Bing Xu Yunfeng Ju |
| author_sort | Liping Liu |
| collection | DOAJ |
| description | This study was designed to assess the effect of additional spironolactone on blood pressure in patients with resistant hypertension. MEDLINE, EMBASE, and Cochrane Library were searched to identify randomized controlled trials (RCTs) that determined the effect of add-on spironolactone on blood pressure in patients with resistant hypertension compared with a control group. A total of five RCTs met the inclusion criteria. Spironolactone reduced office systolic blood pressure (SBP) by 15.73 mmHg (95% CI −20.45 to −11.0; P < 0.00001) and office diastolic blood pressure (DBP) by 6.21 mmHg (95% CI −8.33 to −4.1, P < 0.00001) as compared to placebo group. The pooled changes of 24 h ambulatory or home SBP and DBP were −8.7 mmHg (95% CI −8.79 to −8.62, P < 0.00001) and −4.12 mmHg (95% CI −4.48 to −3.75, P < 0.00001), in favor of the spironolactone group. In comparison with alternative drugs including beta-blocker, candesartan, or alpha methyldopa, spironolactone reduced home SBP by 4.5 mmHg (95% CI −4.63 to −4.37, P < 0.00001). Addition of spironolactone provides benefit effect on blood pressure in patients with resistant hypertension. |
| first_indexed | 2024-03-11T23:46:28Z |
| format | Article |
| id | doaj.art-dd7ad74220244e8da7c0f8f7058bb423 |
| institution | Directory Open Access Journal |
| issn | 1064-1963 1525-6006 |
| language | English |
| last_indexed | 2024-03-11T23:46:28Z |
| publishDate | 2017-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Clinical and Experimental Hypertension |
| spelling | doaj.art-dd7ad74220244e8da7c0f8f7058bb4232023-09-19T09:24:45ZengTaylor & Francis GroupClinical and Experimental Hypertension1064-19631525-60062017-04-0139325726310.1080/10641963.2016.12465641246564Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trialsLiping Liu0Bing Xu1Yunfeng Ju2The Fourth Affiliated Hospital of Nantong Medical UniversityYancheng Institute of TechnologyThe Fourth Affiliated Hospital of Nantong Medical UniversityThis study was designed to assess the effect of additional spironolactone on blood pressure in patients with resistant hypertension. MEDLINE, EMBASE, and Cochrane Library were searched to identify randomized controlled trials (RCTs) that determined the effect of add-on spironolactone on blood pressure in patients with resistant hypertension compared with a control group. A total of five RCTs met the inclusion criteria. Spironolactone reduced office systolic blood pressure (SBP) by 15.73 mmHg (95% CI −20.45 to −11.0; P < 0.00001) and office diastolic blood pressure (DBP) by 6.21 mmHg (95% CI −8.33 to −4.1, P < 0.00001) as compared to placebo group. The pooled changes of 24 h ambulatory or home SBP and DBP were −8.7 mmHg (95% CI −8.79 to −8.62, P < 0.00001) and −4.12 mmHg (95% CI −4.48 to −3.75, P < 0.00001), in favor of the spironolactone group. In comparison with alternative drugs including beta-blocker, candesartan, or alpha methyldopa, spironolactone reduced home SBP by 4.5 mmHg (95% CI −4.63 to −4.37, P < 0.00001). Addition of spironolactone provides benefit effect on blood pressure in patients with resistant hypertension.http://dx.doi.org/10.1080/10641963.2016.1246564spironolactone-resistant hypertension-meta-analysis |
| spellingShingle | Liping Liu Bing Xu Yunfeng Ju Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials Clinical and Experimental Hypertension spironolactone-resistant hypertension-meta-analysis |
| title | Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials |
| title_full | Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials |
| title_fullStr | Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials |
| title_full_unstemmed | Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials |
| title_short | Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials |
| title_sort | addition of spironolactone in patients with resistant hypertension a meta analysis of randomized controlled trials |
| topic | spironolactone-resistant hypertension-meta-analysis |
| url | http://dx.doi.org/10.1080/10641963.2016.1246564 |
| work_keys_str_mv | AT lipingliu additionofspironolactoneinpatientswithresistanthypertensionametaanalysisofrandomizedcontrolledtrials AT bingxu additionofspironolactoneinpatientswithresistanthypertensionametaanalysisofrandomizedcontrolledtrials AT yunfengju additionofspironolactoneinpatientswithresistanthypertensionametaanalysisofrandomizedcontrolledtrials |